Mesothelin and CA 125 expression in digestive carcinoma

本文对110例胃腺癌、91例结直肠癌和61例肝外胆管腺癌进行免疫组织化学检测，并对其在管腔膜中的定位进行分析，以探讨其在癌组织中的表达及其临床病理意义。此外，还利用表达间皮蛋白的结肠癌细胞株进行了淋巴侵袭实验，以检测其生物学作用。在这三种类型的腺癌中，间充质蛋白的“管膜阳性”与患者预后不良显著相关。淋巴管侵袭实验表明，ERC/Mesothelin对结肠腺癌细胞株的侵袭有明显的促进作用。综上所述，间硫蛋白可能成为抑制各种类型消化系统肿瘤通过淋巴系统扩散的新的治疗靶点。(英国癌症杂志)2012年，Int J Oncol.2012，J Gasterenterol。2013年)

In our analysis, 110 cases of gastric, 91 cases of colorectal and 61 cases of extrahepatic bile duct adenocarcinoma were immunohistochemically examined and the localization of mesothelin in luminal membrane was also evaluated to explore the clinicopathological significance of the mesothelin expression in these cancers. In addition, lymphatic invasion assay using the colon cancer cell line with enforced mesothelin expression was also performed to examine its biological role. “Luminal membrane positive” of mesothelin was significantly correlated with unfavorable patients’ outcome in these three types of adenocarcinoma. In addition, lymphatic invasion assay revealed that ERC/mesothelin significantly promoted the invasion of colorectal adenocarcinoma cell lines. In conclusion, mesothelin could be a novel therapeutic target to suppress the spread of tumors through the lymphatic system in various types of digestive cancers. (Br J Cancer. 2012, Int J Oncol.2012, J Gastroenterol. 2013)